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A B S T R A C T
Background: It is not clear whether it is reasonable to use particular drugs for glycemic control in
preference to other hypoglycemic agents in terms of the clinical outcome of percutaneous coronary
intervention (PCI) in patients with diabetes mellitus (DM).
Methods and results: Among 2148 patients (2568 lesions) in the FU-Registry, DM patients who
underwent PCI (n = 758; 922 lesions) were investigated to clarify the effects of various drugs for glycemic
control on the clinical outcome [major adverse cardiac events (MACEs): death, myocardial infarction
(MI), and target lesion revascularization (TLR)] over approximately 300 days of follow-up
(UMIN000005679). The MACEs(+) group (n = 165) had a higher usage of insulin (p < 0.001) and a
lower usage of biguanides (BG, p < 0.05) and dipeptidyl peptidase-IV inhibitors (p < 0.05) at PCI,
compared to the MACEs() group (n = 593). A multivariate logistic regression analysis showed that low-
density lipoprotein cholesterol, insulin use, atherosclerosis obliterans, and lesion reference might be
signiﬁcantly associated with MACEs, while BG use was negatively correlated with MACEs (p = 0.04). The
cumulative frequency of MACEs in the insulin-treated group was signiﬁcantly higher (p < 0.05) than that
in the non-insulin group, and the strongest association between insulin with MACEs was seen in the
hemoglobin (Hb) A1c 6.5–7.5% group. There tended to be a negative correlation between the use of
insulin and MACEs, with risk ratios of <1, for the HbA1c >8.5% groups.
Conclusions: Among different hypoglycemic agents, treatment with insulin was associated with poor
mid-term clinical outcomes in DM patients who underwent PCI, while BG use was negatively correlated
with MACEs. It may be reasonable for patients with HbA1c >8.5% to avoid hyperglycemia and
glucotoxicity, even through the use of insulin.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Percutaneous coronary intervention (PCI) in diabetes mellitus
(DM) patients is associated with higher rates of stent restenosis
and major adverse cardiovascular events (MACEs) compared to PCI
in non-DM patients, and both the short- and long-term outcomes
of treatment are poor [1–4]. Impairment of the vasculargy.
Fig. 1. Outline of the study (the FU-Registry). MACEs were deﬁned to include three
outcomes: all deaths, myocardial infarction, and target lesion revascularization.
ACS, acute coronary syndrome; MACEs, major adverse cardiovascular event.
A. Ike et al. / Journal of Cardiology 65 (2015) 390–396 391endothelium [5] by chronic hyperglycemia, which magniﬁes the
inﬂammatory response [6] and accelerates cellular proliferation
[7], and the existence of pathological conditions that aggravate
vascular impairment, such as accentuation of the blood coagula-
tion system [8], have been reported to be the causative factors, and
this remains a problem despite the emergence of the drug-eluting
stent (DES) and a decline in stent restenosis [9].
Although suppression of the onset of cardiovascular disease
(CVD) in the long-term by proactive glycemic control using insulin
and sulfonylurea (SU) agents has been established, as proven by
studies such as UKPDS 80 [10], the Framingham Study [11], and
DCCT/EDIC [12], there has been no difference in the incidence of
cardiovascular events during follow-up periods of <10 years
[13,14]. In a previous report, we showed that proactive glycemic
control initiated at the time of PCI does not improve the clinical
outcome of PCI in the mid-term [4]. However, due to the design of
the study, many points regarding the association between the
hypoglycemic agents and the clinical outcome were not clear. In
addition, it is not clear whether it would be better to use any
particular drugs for glycemic control in preference to other
hypoglycemic agents including insulin, in terms of the clinical
outcome of PCI in DM patients. Therefore, we compared mid-term
clinical outcomes, including angiographic analyses, at an average
of 9 months after PCI in DM patients who were divided into
MACEs(+) and MACEs() groups, to clarify the association between
the use of hypoglycemic agents and outcome.
Methods
Patients
The FU-Registry was established in 2003 and combines PCI data
from the Fukuoka University Hospital Group. We performed an
angiographical analysis using the database from the FU-Registry
[UMIN000005679, Fukuoka University Hospital EC/IRB: 10-1-
08(09-105)].
Patients with DM were extracted from among the total 2148
patients (2568 lesions) in whom PCI was performed during the
period from January 2003 to July 2012 at Fukuoka University
Hospital, Fukuoka University Chikushi Hospital, and Hakujyuji
Hospital in Fukuoka. The comparisons were made by ﬁrst
excluding patients with non-DM, acute coronary syndrome
(ACS), and hemodialysis (HD), and then dividing the remaining
758 cases (922 lesions) into a MACEs() group (593 cases; 754
lesions) and a MACEs(+) group (165 cases; 168 lesions) (Fig. 1). The
average follow-up period was 300 days, clinical follow-up was
carried out in all cases, and the presence or absence of MACEs was
conﬁrmed at the last outpatient visit, or by telephone interview in
some cases. Angiographic follow-up was performed for approxi-
mately 95% of the full cohort. Patients were considered to have DM
if any of the diagnostic criteria deﬁned by the Japan Diabetes
Society [fasting blood sugar level  126 mg/dl, 2-h 75 g oral
glucose tolerance test (OGTT) glucose level  200 mg/dl or random
blood sugar level  200 mg/dl (venous plasma levels)] were met,
or if they continued the oral administration of hypoglycemic drugs
with a clear diagnosis of DM, as described previously [4].
Measurements and deﬁnitions
The hemoglobin (Hb) A1c value was evaluated according to
the US National Glycohemoglobin Standardization Program
(NGSP) [15]. MACEs were deﬁned to include three outcomes:
all deaths, myocardial infarction (MI), and target lesion revascu-
larization (TLR). MI included both ST elevation MI and non-ST
elevation MI, either with clear ischemic electrocardiographic
changes or with elevated cardiogenic enzymes [positive rapidtroponin T, creatine kinase (CK) greater than double the reference
level, CK-MB greater than the upper limit of the reference levels].
Stent thrombosis was considered to include deﬁnite, probable,
and possible according to the deﬁnition of the ARC (Academic
Research Consortium) [16].
PCI intravascular ultrasound procedure
PCI was performed in cases in which there was >50% stenosis
angiographically with either chest symptoms or proof of ischemia
by non-invasive tests (treadmill stress electrocardiogram, myo-
cardial scintigraphy). The end-point of the technique was the
absence of any dissection resulting in the obstruction of blood ﬂow,
achievement of thrombolysis in MI III ﬂow and <10% stenosis
angiographically. The decision to perform intravascular ultrasound
(IVUS) was made by the cardiologists, and it was performed in
approximately 1/3 of all cases. With regard to pre-procedural IVUS,
cases in which lesions were not crossed were not included in the
present analysis and only the results of post-procedural IVUS
measurements were used.
Medication (antiplatelets)
With regard to antiplatelet agents, in all cases, aspirin and
either ticlopidine 200 mg or clopidogrel 75 mg were started at
least 48 h before stent insertion. In principle, in cases with a bare-
metal stent (BMS), antiplatelet agents other than aspirin were
continued for at least 2 weeks, and in cases with a DES, all
antiplatelet agents were administered for at least 9 months after
PCI. Insulin included different types of insulin, and thiazolidine
(pioglitazone), dipeptidyl peptidase (DPP)-IV inhibitors (sitagliptin,
vildagliptin, alogliptin), Sulfonylureas (SU; gliclazide, glibencla-
mide, glimepiride), biguanides (BG; metformin hydrochloride), and
a-glucosidase inhibitor (a-GI; acarbose, voglibose, miglitol) were
mostly used in this registry.
Quantitative coronary angiography
Quantitative coronary angiography (QCA) was carried out
randomly in approximately 70% of all cases. Quantitative and
qualitative analyses were made at the core laboratory of Fukuoka
University, using CMS-GFT (MEDIS, Leiden, The Netherlands), as
described previously [4,17,18]. Analyses were made for pre-
procedural, post-procedural, and follow-up angiograms. All
measurements were made using images after the intracoronary
injection of nitroglycerin. Segments were deﬁned as in-stent, the
Table 1
Patient and lesion characteristics in the MACEs(+) and MACEs() groups.
MACEs()
group
MACEs(+)
group
N = 593 N = 165
Patient characteristics
Mean age (year) 67.9  9.7 68.1  9.8
Gender (male) (%) 70.6 79.9*
BMI (kg/m2) 24.1  3.5 24.2  3.0
UCG-LVEF (%) 61.6 60.6
Blood sampling test at PCI procedure
Cr (mg/dl) 1.00  0.49 1.02  0.40
TC (mg/dl) 179.9  39.2 188.6  45.7*
TG (mg/dl) 141.3  94.7 134.8  71.2
HDL-C (mg/dl) 48.3  12.7 46.5  11.8
LDL-C (mg/dl) 102.8  33.9 115.5  39.9z
Non-HDL-C (mg/dl) 131.9  37.9 142.8  45.8y
LDL-C/HDL-C 2.3 2.7z
HbA1c (%) 7.0  1.2 7.1  1.3
Follow-up data
BMI (kg/m2) 24.2  3.8 24.5  3.2
Blood sampling test at follow-up
TC (mg/dl) 170.5  39.5 178.5  37.2*
TG (mg/dl) 143.3  141.6 132.8  67.9
HDL-C (mg/dl) 50.6  13.1 48.0  12.6*
LDL-C (mg/dl) 90.1  29.2 103.8  33.9z
Non-HDL-C (mg/dl) 119.5  39.7 131.6  37.3y
LDL-C/HDL-C 1.9 2.4z
HbA1c (%) 6.9  1.3 6.9  1.2
Prior diseases/complicated diseases
Prior MI (%) 25.6 29.7
Prior PCI (%) 45.4 59.4y
Prior CABG (%) 5.1 7.3
ASO (%) 9.4 20.6z
Hypertension (%) 80.8 73.9*
Hyperlipidemia (%) 77.2 70.3
Medications at PCI procedure
Ca blockers (%) 53.8 47.9
ACEIs (%) 13.2 15.1
b-Blockers (%) 11.5 15.8
Statins (%) 74.4 76.4
ARBs (%) 67.5 73.3
N = 754 N = 168
Lesion characteristics
3 vessel disease (%) 47.1 41.1
RCA/LAD/CX (%) 30.7/46.2/17.2 30.1/52.2/15.4
LMT lesion (%) 3.3 1.9
Prior in stent
restenosis (%)
15.1 35.7y
AHA/ACC type
B2 + C (%)
61.1 63.7
Severe calciﬁcation (%) 12.3 13.3
Drug eluting stent (%) 64.5 58.3*
QCA N = 594 N = 117
Pre-procedural results
Lesion length (mm) 18.4  10.1 21.5  12.9*
Reference diameter
(mm)
2.6  0.6 2.4  0.6y
MLD (mm) 0.8  0.4 0.7  0.4
%DS (%) 71.1 70.9
Post-procedural results
MLD (mm) 2.0  0.6 1.9  0.6
%DS (%) 24.6 25.2
Stent length (mm) 22.7  11.5 25.5  13.6
Stent MLD (mm) 2.5  0.5 2.4  0.5
Stent reference (mm) 2.8  0.5 2.8  0.4
Stent %DS (%) 11.4 14.5
N = 244 N = 69
IVUS (post-procedural results)
Lesion EEM
CSA (mm2)
14.1  5.0 12.5  4.3y
Lesion lumen
CSA (mm2)
6.4  2.5 5.7  1.8y
Lesion atheroma
CSA (mm2)
7.7  3.3 6.8  3.4*
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stent. Late-loss was deﬁned as the difference between the
minimum lesion diameter (MLD) in the post-procedural angio-
gram and the MLD in the follow-up angiogram. In addition,
restenosis was deﬁned as >50% stenosis.
Statistical analysis
Statistical analysis was carried out at the University of Fukuoka
using SAS software (Version 9.1, SAS Institute, Cary, NC, USA). The
chi-square test was used for comparisons of categorical variables
between groups. The Wilcoxon rank sum test and the Student’s t-
test were used for comparisons of continuous variables between
groups shown as the mean  SD. The multiple logistic regression
analysis was used to examine the independent association between
variables of patient and lesion characteristics and MACEs [19]. To
examine the independent association between variables of patient
characteristics and MACEs, conventional risk factors of CVD, including
age, gender, body mass index (BMI), and hypertension, and variables
of patient characteristics that were associated with MACEs in the
univariate analysis, including serum lipids, HbA1c, and hypoglycemic
agents, were included in the regression model. To examine the
independent association between variables of lesion characteristics,
variables of lesion characteristics that were associated with MACEs in
the univariate analysis were included in the regression model. For
variables that were strongly correlated, only one variable was
included in the model to avoid multicollinearity. The cumulative
frequency of MACEs for each follow-up period in patients with and
without insulin use was calculated as the percentage of the number of
patients who had MACEs during that period in total number of
patients in each group, respectively. The association between insulin
use and MACEs after controlling follow-up period was assessed by
Cochran–Mantel–Haenszel test [19]. A p value <0.05 was considered
to be statistically signiﬁcant.
Results
Factors that most strongly predict MACEs after PCI
With regard to follow-up clinical outcomes of MACEs in this
registry, the incidence of TLR-PCI, TLR-coronary artery bypass graft
(CABG), MI, and death were 85.4%, 4.2%, 10.9%, and 9.1%,
respectively. Table 1 shows the patient characteristics in the
MACEs(+) and MACEs() groups. The MACEs(+) group included
more males (p < 0.05), and showed higher levels of low-density
lipoprotein cholesterol (LDL-C) (p < 0.001), non-high-density
lipoprotein cholesterol (non-HDL-C) (p < 0.01), and lower HDL-C
levels at PCI and at the 9-month to 1-year follow-up. The MACEs(+)
group was also more likely to have had prior PCI (p < 0.01) and
atherosclerosis obliterans (ASO) (p < 0.001), and less hypertension
(p < 0.05). The MACEs(+) group showed a higher frequency of prior
in-stent restenosis (p < 0.05) and a lower use of a DES (p < 0.05). In
addition, the lesion length was greater (p < 0.05) and the reference
diameter was smaller (p < 0.01) in the MACEs(+) group, while
post-procedural IVUS parameters were signiﬁcantly smaller in the
MACEs(+) compared to MACEs() group, except lesion % plaque
(Table 1).
Association between the hypoglycemic agents used and MACEs
Table 2 shows the hypoglycemic drugs used. The MACEs(+)
group was more likely to be receiving insulin therapy (p < 0.001)
and less likely to be receiving BG (p < 0.01) or DPP-IV inhibitors
(p < 0.05), at both the PCI procedure and the follow-up periods
(over approximately 300 days).
Table 1 (Continued )
N = 244 N = 69
Lesion % plaque (%) 53.8 54.1
Minimum stent
CSA (mm2)
6.6  3.2 5.8  1.8y
BMI: body mass index, UCG LVEF: ultrasound cardiography left ventricle
ejection fraction, Cr: creatinine, TC: total cholesterol, TG: triglyceride, HDL-C:
high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol,
Non-HDL-C: non high density lipoprotein cholesterol, MI: myocardial infarc-
tion, PCI: percutaneous coronary intervention, CABG: coronary artery bypass
graft, ASO: arteriosclerosis obliterans, ACEIs: angiotensin-converting enzyme
inhibitors, ARBs: angiotensin II receptor blockers, RCA: right coronary artery,
LAD: left anterior descending coronary artery, CX: left circumﬂex coronary
artery, LMT: left main trunk, MLD: minimum lumen diameter, %DS: percent
diameter stenosis, CSA: cross sectional area, EEM: external elastic membrane.
* p < 0.05.
y p < 0.01.
z p < 0.001.
Table 2
Hypoglycemic agents used in the MACEs(+) and MACEs() groups.
MACEs() group MACEs(+) group
Medications for DM at procedure
Sulfonylurea (%) 31.9 25.5
a-GIs (%) 21.4 21.8
Thiazolidines (%) 11.6 13.3
Insulin (%) 27.8 40.0z
Biguanides (%) 8.3 3.6*
DPP-IV inhibitors (%) 8.8 2.4*
Medication for DM at follow-up
Sulfonylurea (%) 32.5 29.7
a-GIs (%) 21.4 16.9
Thiazolidines (%) 13.0 13.3
Insulin (%) 19.6 38.9z
Biguanides (%) 10.1 9.0
DPP-IV inhibitors (%) 10.6 5.4*
a-GI, a-glucosidase inhibitor.
* p < 0.05.
z p < 0.001.
Table 3
Multivariate logistic regression analysis of the association between variables of
patient and lesion characteristics and MACEs.
p value Odds ratio (95% CI)
Patient characteristics of pre-procedural
Age 0.46 1.01 (0.99–1.03)
BMI 0.99 1.04 (0.94–1.05)
Gender 0.70 1.10 (0.68–1.81)
HDL-C 0.06 0.98 (0.97–1.00)
LDL-C 0.003 1.01 (1.01–1.02)
HbA1c 0.28 0.91 (0.76–1.08)
Insulin 0.007 1.87 (1.19–2.93)
Biguanides 0.06 0.44 (0.09–1.02)
Sulfonylurea 0.46 0.83 (0.50–1.35)
DPP-IV inhibitors 0.12 0.30 (0.10–1.47)
Prior PCI 0.05 1.68 (0.99–2.53)
ASO 0.001 2.31 (1.38–3.87)
Hypertension 0.29 0.77 (0.47–1.26)
Lesion characteristics
Drug eluting stent 0.97 1.00 (0.92–1.09)
Prior in-stent restenosis 0.11 2.14 (0.81–5.51)
Lesion length 0.41 1.50 (0.59–4.18)
Lesion references (pre-procedural results) 0.01 0.28 (0.10–0.68)
Lesion EEM CSA 0.54 1.09 (0.84–1.52)
Lesion atherome CSA 0.26 0.81 (0.54–1.15)
Stent minimum CSA 0.80 1.02 (0.76–1.17)
BMI, body mass index; TC, total cholesterol; HDL-C, high-density lipoprotein
cholesterol; LDL, low-density lipoprotein cholesterol; ASO, arteriosclerosis
obliterans; CSA, cross-sectional area; EEM, external elastic membrane; CSA,
cross-sectional area.
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group] and non-insulin users [Insulin() group] among patients with
MACEs
The clinical characteristics, including gender, BMI, left ventric-
ular ejection fraction, blood examinations at PCI procedure and
at follow-up, prior MI, prior CABG, etc., were all similar between
the groups, while there were differences in ASO and lesion
references (mm) in pre-procedural QCA, i.e. the Insulin(+)
group had a higher incidence of ASO (19.5% vs. 10.4%, p < 0.01),
while the lesion references (mm) in pre-procedural QCA were
shorter (2.4  0.6 mm vs. 2.6  0.6 mm, p < 0.01), compared to the
Insulin() group (data not tabulated).
Multivariate logistic regression analysis
Table 3 shows the results of a multivariate logistic regression
analysis of the patient and lesion characteristics and MACEs(+).
LDL-C (p = 0.003), insulin use (p = 0.007), ASO (p = 0.001), and the
lesion reference (p = 0.01) were signiﬁcantly associated with
MACEs(+). Only hypoglycemic agents were extracted to examine
their relationship to MACEs by multivariate logistic regression
analysis, and, as expected, insulin use showed a strong positive
correlation with MACEs [odds ratio: 1.58 (95% CI: 1.06–2.37),
p = 0.02]. On the other hand, BG use showed a negative correlation
with MACEs [odds ratio: 0.34 (95% CI: 0.1–0.87), p = 0.04] (Fig. 2A
and B). While the odds ratio for DPP-IV inhibitors was below 1.0,
this result was not signiﬁcant (Fig. 2A and B).
Effects of insulin use on the cumulative frequency of MACEs
The effects of insulin use on the cumulative frequency of MACEs
are shown in Fig. 3. Insulin use was associated with an increase in
MACEs as follow-up period increased (p = 0.005).
Association of insulin use with MACEs according to the value of HbA1c
The entire cohort of 758 DM cases in the present study was
further stratiﬁed according to the HbA1c value at PCI into a <6.5%
group (148 cases), 6.5–7.5% group (218 cases), 7.5–8.5% group (125
cases), 8.5–9.5% group (65 cases), and >9.5% group (49 cases), and
the association between insulin and MACEs was studied in each
group (Fig. 4). As a result, the strongest association between insulin
and MACEs was seen in the HbA1c 6.5–7.5% group (p < 0.0001,
odds ratio: 3.23, 95% CI: 1.6–6.5).
In addition, in the other groups, although there were no
signiﬁcant differences, there tended to be a negative correlation
between the use of insulin and MACEs, with odds ratios of <1 for
the HbA1c 8.5–9.5% and >9.5% groups.
Discussion
There have been many reports, such as UKPDS 80 [10] and
DCCT/EDIC [12], on the suppressive effect of proactive glycemic
control by consolidation therapy, including insulin, on cardiovas-
cular events in the long term (more than a decade). However,
studies such as DCCT [14] and UKPDS [13] have reported that,
although microangiopathy was signiﬁcantly suppressed in a
consolidation therapy group, no difference was found in the
incidence of cardiovascular events between a consolidation
therapy group and an ordinary therapy group. Further, in the
ACCORD trial [20], while follow-up was discontinued after 3.5
years because of an increase in total deaths, there was no
difference in the incidence of cardiovascular events between the
consolidation therapy group and the ordinary therapy group.
Based on these reports, it is reasonable to consider that appropriate
Fig. 2. (A) and (B) The relationship between hypoglycemic agents and major adverse cardiovascular events was examined by a multivariate logistic regression analysis (only
hypoglycemic agents were extracted), after adjusting for confounding variables. a-GI, a-glucosidase inhibitor; DPP, dipeptidyl peptidase.
A. Ike et al. / Journal of Cardiology 65 (2015) 390–396394consolidation therapy, without hypoglycemia, reduces the inci-
dence of cardiovascular events in the long term and the incidence
of microangiopathy in the short term.
In our study, BG (p = 0.04), SU (ns) and DPPIV inhibitors
(p = 0.17) were tend to be associated with a lower incidence of
MACEs (Fig. 2A and B), while insulin (p = 0.02), thiazolidines
(p = 0.13), and a-GI (p = 0.66) were shown to promote MACEs.
Since Tables 2 and 3 and Fig. 2A and B showed that insulin use was
a major cause of MACEs, the time-line of cumulative MACEs wasFig. 3. The cumulative frequency of major adverse cardiovascular events (MACEs) in
the overall patients with Insulin(+) (red) and Insulin() (black). The cumulative
frequency of MACEs for each follow-up period in patients with and without insulin
use was calculated as the percentage of the number of patients who had MACEs
during that period in total number of patients in each group, respectively. The
association between insulin use and MACEs after controlling follow-up period was
assessed by Cochran–Mantel–Haenszel test [19].analyzed (Fig. 3). Insulin therapy was associated with an increase
in MACEs in the patients overall, as follow-up period increased.
Insulin is thought to have both an atherosclerosis-suppressive
effect and an atherosclerosis-inducing effect, and it is not clear how
the physiological effect of insulin is involved in the results of the
aforementioned large-scale trials. The atherosclerosis-suppressive
effects of insulin include activation of the mechanism of NO
production in vascular endothelial cells [21–23] which, through
NO, is thought to promote vasorelaxation, the inhibition of plateletFig. 4. The association of insulin use with major adverse cardiovascular events
according to the value of hemoglobin (Hb) A1c. Positive and negative correlations
were observed at below and above an HbA1c value of 8.5%, respectively.
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muscle. The atherosclerosis-inducing effects include accentuation
of the renin–angiotensin system [24] and platelet activity as well
as the direct proliferation of smooth muscle cells [25,26] through
the activity of the sympathetic nervous system [27]. A recent
report that considered the initiation of insulin rather than the
addition of another oral glucose-lowering drug to double or triple
oral therapy did not show a signiﬁcant increase in vascular events
[28]. A single bedtime dose of insulin was reported to be safe and
effective, and did not inﬂuence in-stent restenosis [29]. Therefore,
atherosclerosis-suppressive and atherosclerosis-inducing effects
are counterbalanced in the human body.
The standard use of stents at PCI and insulin therapy have
changed over time, and the long study period have affected the
results. However, in the present study, lesion stent late loss, which
represents the degree of neointimal proliferation, in the Insulin(+)
group was signiﬁcantly greater than that in the Insulin() group
(0.45  0.72 mm vs. 0.27  0.66 mm, respectively, data not tabulat-
ed), despite similar patient and lesion characteristics and similar
usage rates of DES (around 60%), to result in a higher in-stent
restenosis rate (35.4% vs. 21.3%, respectively).
The incidences of MI and stent thrombosis were also
signiﬁcantly higher in the Insulin(+) group. While the details of
the occurrence of hypoglycemia are not clear, there was no
difference between the mortality rates in the two groups. In the
multivariate analysis (Table 3), insulin showed the second
strongest association with MACEs after ASO, suggesting that the
atherosclerosis-inducing effect of insulin is stronger than the
atherosclerosis-suppressive effect in the area where PCI has been
performed. However, these results do not allow us to conclusively
state whether it is better to not use insulin for patients in whom PCI
is performed.
The strongest association between insulin with MACEs was
seen in the HbA1c 6.5–7.5% group. In the HbA1c 8.5–9.5% and over
9.5% groups, the use of insulin might be associated with lower
incidences of MACEs (Fig. 4). Therefore, in patients who have
undergone PCI, it may be beneﬁcial to introduce insulin therapy for
HbA1c values >8.5%.
Oral DPP-IV inhibitors have also been shown to provide
reasonable reductions in HbA1c along with other oral glucose-
lowering drugs, raise levels of the incretin glucagon-like peptide-1
(GLP-1), and inhibit the release of glucagon [30,31]. They have been
shown to improve endothelial function through anti-inﬂammatory
effects, beyond their hypoglycemic action [32]. In our study, use of
DPP-IV inhibitors and BG in MACEs(+) were lower than those in
MACEs() at PCI, albeit this effect was not statistically signiﬁcant
by a multivariate logistic regression analysis. During insulin
therapy, we should seek to improve the constitution of DM
patients, and ultimately should seek to discontinue treatment with
insulin due to improved insulin sensitivity. This approach may be
associated with an improvement in the mid-term clinical out-
comes of DM patients who undergo PCI. In this context, the use of a
new DPP-IV inhibitor may be useful for DM patients who undergo
PCI.
Limitations
The present study was not a prospective cohort study and
included patients in whom PCI was performed from 2003 to 2012.
Insulin levels were not measured, and we did not collect detailed
DM data, such as information regarding blood sugar control before
PCI and the medical history of DM (such as how long the patients
had had DM and the number of years they had been treated).
Information regarding the amounts or types of insulin used in the
present study was not clear, and thus we could not examine the
effects of these factors.Conclusion
Among different hypoglycemic agents, treatment with insulin
was associated with poor mid-term clinical outcomes in DM
patients who underwent PCI, while the use of BG was negatively
correlated with MACEs. Since the use of insulin was associated
with a lower incidence of MACEs in patients with HbA1c >8.5%, it
may be beneﬁcial to control hyperglycemia in these patients even
with the use of insulin.
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